High-Dose Chemotherapy in High-Risk Primary Breast Cancer

Publisher： Karger

E-ISSN： 2296-5262|25|2|112-120

ISSN： 2296-5270

Source： Oncology Research and Treatment, Vol.25, Iss.2, 2002-05, pp. : 112-120

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Long-Term Efficiency and Toxicity of Adjuvant Dose-Dense Sequential Adriamycin-Paclitaxel-Cyclophosphamide Chemotherapy in High-Risk Breast Cancer

By  

Oncology, Vol. 78, Iss. 3-4, 2010-06 ,pp. : 271-273

Karger

Access to resources Recommend Favorite

Dose-Dense Sequential Adriamycin-Paclitaxel-Cyclophosphamide Chemotherapy Is Well Tolerated and Safe in High-Risk Early Breast Cancer

By  

Oncology, Vol. 68, Iss. 4-6, 2005-08 ,pp. : 446-453

Karger

Access to resources Recommend Favorite

Dose-Dense Sequential Adjuvant Chemotherapy with Epirubicin, Paclitaxel and CMF in High-Risk Breast Cancer

By  

Oncology, Vol. 60, Iss. 3, 2001-04 ,pp. : 214-220

Karger

Access to resources Recommend Favorite

Is high-dose chemotherapy with autologous hematopoietic stem cell transplantation in breast cancer patients a done deal?

By Cheng Yee Chung   Ueno Naoto T  

Women's Health, Vol. 6, Iss. 4, 2010-07 ,pp. : 481-485

Future Medicine

Access to resources Recommend Favorite

High-Dose Therapy for Breast Cancer – A Case of Suspended Animation

By  

Acta Haematologica, Vol. 114, Iss. 4, 2005-11 ,pp. : 248-254

Karger

Access to resources Recommend Favorite